Florida / New York
Ph: 561.316.3330
The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.
Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a “Breakthrough Device” by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.
Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics’ VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.
Mindray notes this medical education series is aimed at the growing demand within the anesthesiology community to integrate ultrasound and AI technology at the bedside, demonstrating the company’s commitment to advancing ultrasound training and technology adoption.
Brain-CA Technologies, a leading innovator in artificial intelligence solutions, is proud to announce the issuance of US Patent No. 11847386B1 and US Patent No. 12050846B1, unveiling their latest breakthrough in AI technology.
“Introduction of Annexin V StarBright Dye conjugates offers customers greater choice and flexibility when detecting apoptosis in both conventional and full spectrum flow cytometry,” said Hilary Mavor, Marketing Director, Life Science Group at Bio-Rad Laboratories. “Bio-Rad has one of the most comprehensive ranges of annexin V conjugates, allowing users to follow best practice and accurately detect apoptosis with minimum spillover with their viability dyes.”
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330